Abbott Share Price Today | Stock Price & Abbott Share Screener
As of October 21, 2026, the live Abbott share price (NSE: ABBOTINDIA) is ₹25,680.00 on NSE and ₹25,744.40 on BSE, down 0.87% from the previous close, with shares trading between ₹25,135.00 and ₹26,055.00 in today's trading session, and a 52-week range of ₹25,180.00–₹30,205.00. Check ABBOTINDIA annual price range for the annual price range and momentum. Use the Abbott stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Abbott opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹7,295 and net income of ₹1,615, with EBITDA of ₹2,260, an operating margin of 28.0% and a profit margin of 22.1%.
Abbott Share Price Chart
Track the current stock price of Abbott with an interactive chart. Analyse ABBOTINDIA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Abbott stock quote in one place.
The quote of ₹25,680.00 sits between the 52-week low of ₹25,180.00 and the 52-week high of ₹30,205.00, and the latest session moved -0.87% from the previous close.
Abbott Company Profile - Fundamental Screener
Screen Abbott company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ABBOTINDIA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Munir Shaikh listed as chairperson or CEO, and it trades under ISIN INE358A01014.
Business Overview
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic...more
Company Details
Classification
Identifiers and Leadership
Abbott Balance Sheet Screener
Screen ABBOTINDIA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹6,502, up from ₹5,917 in 2025.
Latest statistics put total assets at ₹6,502 and shareholder funds at ₹4,774, with a leverage ratio of 0.04.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 6,502 | 5,917 | 5,194 | 4,556 | 4,224 | 3,840 | 3,547 | 2,941 | 2,416 | 2,066 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 331 | 336 | 225 | 237 | 271 | 251 | 270 | 105 | 81 | 110 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 251 | 277 | 152 | 161 | 201 | 207 | 224 | 75 | 55 | 47 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4,774 | 4,233 | 3,699 | 3,189 | 2,820 | 2,602 | 2,432 | 2,009 | 1,693 | 1,387 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves & Surplus | 4,753 | 4,212 | 3,678 | 3,167 | 2,799 | 2,581 | 2,411 | 1,987 | 1,672 | 1,366 |
Abbott Income Statement Screener - Profit & Revenue Analysis
Screen Abbott income statement and profit fundamentals. Analyze ABBOTINDIA quarterly results. Abbott reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹7,295 and net profit was ₹1,615, equal to earnings per unit of ₹759.80, at an operating margin of 28%.
In that period expenses were ₹5,036, interest cost ₹25 and tax ₹557. The next period listed, 2026-March, shows revenue of ₹7,217 and net profit of ₹1,552.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 7,295 | 7,217 | 6,685 | 6,097 | 5,503 | 4,997 | 4,391 | 4,208 | 3,792 | 3,416 | 2,960 | 2,665 | 2,337 |
| Expenses | 5,036 | 5,037 | 4,715 | 4,396 | 4,143 | 3,832 | 3,389 | 3,337 | 3,074 | 2,774 | 2,505 | 2,250 | 1,977 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 2,260 | 2,180 | 1,970 | 1,701 | 1,360 | 1,165 | 1,002 | 871 | 718 | 642 | 455 | 415 | 360 |
| Operating Profit % | 28.00% | 27.00% | 26.00% | 25.00% | 23.00% | 22.00% | 21.00% | 18.00% | 16.00% | 16.00% | 14.00% | 14.00% | 13.00% |
| Depreciation | 76 | 76 | 72 | 71 | 70 | 66 | 58 | 60 | 17 | 16 | 16 | 14 | 15 |
| Interest | 25 | 25 | 11 | 12 | 16 | 19 | 18 | 9 | 2 | 4 | 2 | 3 | 1 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 2,158 | 2,079 | 1,887 | 1,618 | 1,274 | 1,080 | 926 | 803 | 699 | 622 | 437 | 398 | 344 |
| Tax | 557 | 527 | 473 | 417 | 324 | 281 | 235 | 210 | 249 | 220 | 160 | 143 | 115 |
| Net Profit | 1,615 | 1,552 | 1,414 | 1,201 | 949 | 799 | 691 | 593 | 450 | 401 | 277 | 255 | 229 |
| EPS | 759.80 | 730.36 | 665.62 | 565.28 | 446.80 | 375.87 | 325.04 | 279.04 | 211.93 | 188.81 | 130.19 | 120.12 | 107.75 |
Abbott Cash Flow Screener - Liquidity Fundamentals
Screen ABBOTINDIA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹1,319, and net cash flow was an outflow of ₹118.
Over the same period, investing activities used ₹371 and financing activities used ₹1,066.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 1,319 | 1,012 | 1,213 | 893 | 948 | 727 | 626 | 499 | 153 | 307 |
| Investing Activities | -371 | 182 | -416 | -148 | -396 | -72 | -401 | -257 | -215 | -155 |
Financing and Net Cash | ||||||||||
| Financing Activities | -1,066 | -925 | -745 | -639 | -637 | -582 | -217 | -143 | -102 | -90 |
| Net Cash Flow | -118 | 269 | 52 | 107 | -86 | 73 | 8 | 99 | -165 | 62 |
Abbott Shareholding Pattern Screener
See Abbott shareholding pattern with promoter, FII, and DII holdings. Check Abbott promoter holding and ownership changes for ABBOTINDIA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 74.99%, foreign institutions 0.26%, domestic institutions 8.93% and the public 13.38%, spread across 75,866 shareholders.
The shareholder count was 75,866 in 2026-Mar, compared with 78,320 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% |
Institutional Investors | ||||||||
| FII Holding | 0.26% | 0.38% | 0.40% | 0.16% | 0.16% | 0.16% | 0.18% | 0.18% |
| DII Holding | 8.93% | 8.78% | 8.99% | 8.92% | 9.19% | 9.11% | 9.00% | 8.91% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.38% | 13.41% | 13.19% | 13.66% | 13.35% | 13.43% | 13.42% | 13.80% |
| Other Holding | 2.43% | 2.44% | 2.44% | 2.28% | 2.31% | 2.31% | 2.42% | 2.12% |
| Shareholder Count | 75,866 | 78,320 | 75,769 | 69,934 | 67,584 | 71,199 | 75,801 | 69,382 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Abbott. Abbott dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹656.00 per unit for 2026-March, a yield of 2.51%, compared with ₹475.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹656.00, ₹475.00 and ₹410.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹656.00 | 2.51% |
| 2025-March | ₹475.00 | 1.83% |
| 2024-March | ₹410.00 | 1.33% |
| 2023-March | ₹325.00 | 1.20% |
| 2022-March | ₹275.00 | 1.26% |
| 2021-March | ₹275.00 | 1.55% |
| 2020-March | ₹250.00 | 1.67% |
| 2019-March | ₹65.00 | 0.42% |
| 2018-March | ₹55.00 | 0.75% |
| 2017-March | ₹40.00 | 0.73% |
Abbott Stock Index Membership - Nifty & Sensex
See which indices include Abbott stock. Check ABBOTINDIA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 25 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE200.
Complete Index List
Abbott Market Events Screener - Corporate Actions
Get Abbott corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Abbott stock events that may affect ABBOTINDIA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated August 13, 2026, with a record date of August 13, 2026.
It is followed by Quarterly Result Announcement dated August 12, 2026 and Dividend dated July 24, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-13 | 2026-08-13 | Annual General Meeting | NA | 5.57% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | 0.45% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 131.00 /share | 7.78% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 525.00 /share | 7.78% |
| 2026-05-11 | 2026-05-11 | Quarterly Result Announcement | NA | 4.62% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 0.09% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -1.36% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | 6.57% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.83% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 475.00 /share | 13.94% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 0.67% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | -1.42% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 2.06% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | 8.45% |
| 2024-07-19 | 2024-07-19 | Dividend | ₹ 410.00 /share | 10.98% |
Abbott Competitors Screener - Peer Stocks Comparison
Screen ABBOTINDIA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 421,995 | 34.86 | 61,674 | 12.69% | 11,565 | 37.01 |
| Divis Laboratories | 242,758 | 82.05 | 11,067 | 13.95% | 2,568 | 46.92 |
| Torrent Pharmaceuticals | 173,406 | 81.26 | 13,886 | 20.34% | 2,138 | 32.77 |
| Zydus Life Science | 112,020 | 24.78 | 27,658 | 17.64% | 5,026 | 44.73 |
| Laurus Labs | 111,310 | 100.10 | 6,868 | 22.01% | 890 | 60.45 |
| Cipla | 107,049 | 32.11 | 29,045 | 2.24% | 3,870 | 40.32 |
| Dr Reddys Laboratories | 102,916 | 32.01 | 35,059 | 3.90% | 4,158 | 57.84 |
| Aurobindo Pharma | 95,910 | 25.97 | 34,145 | 5.56% | 3,503 | 47.98 |
| Mankind Pharma | 93,988 | 47.04 | 14,636 | 14.85% | 1,938 | 37.77 |
| Lupin | 89,702 | 16.14 | 29,039 | 26.75% | 5,356 | 35.35 |
Abbott Company Announcements - News & Reports Screener
Screen ABBOTINDIA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 6, 2026.
The next most recent announcements are dated October 2, 2026 and September 28, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-13 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-12 | Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-08-12 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-08-04 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30 2026. | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-20 | Communication Providing The Weblink Including Path Of Annual Report. | - |
| 2026-07-20 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-20 | Annual General Meeting On August 13 2026. | - |
| 2026-07-20 | Reg. 34 (1) Annual Report. | - |
| 2026-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-17 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-06-15 | Communication To Shareholders - Intimation About Tax Deduction At Source On Dividend | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹25,680.00, within a 52-week range of ₹25,180.00 to ₹30,205.00. The P/E ratio is 34.31 and the P/B ratio is 11.60, with earnings per unit of ₹730.36. Market capitalisation stands at ₹55,609.42 Cr and the dividend yield is 2.52%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 22, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.